Catfish Egg Lectin Enhances the Cytotoxicity of Sunitinib on Gb3-Expressing Renal Cancer Cells

• Published in: Biomedicines Vol. 11; no. 8; p. 2317
• Main Authors: Ito, Jun, Sugawara, Shigeki, Tatsuta, Takeo, Hosono, Masahiro, Sato, Makoto
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01-08-2023; MDPI
• Subjects: Antimitotic agents; Antineoplastic agents; Antitumor agents; Apoptosis; Cancer; Cancer therapies; Care and treatment; Cell viability; Cells; Cytotoxicity; Drug dosages; Globotriaosylceramide; Intracellular; Kidney cancer; Kinases; Laboratories; Lectins; Metastases; Metastasis; Permeability; Propidium iodide; Renal cell carcinoma; rhamnose-binding lectin; sunitinib; Vascular endothelial growth factor; Japan; Austria; United States > US; Germany
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines11082317

Metastatic renal cell carcinoma (RCC) is not sufficiently responsive to anticancer drugs, and thus, developing new drugs for advanced RCC remains vital. We previously reported that the treatment of globotriaosylceramide (Gb3)-expressing cells with catfish (Silurus asotus) egg lectin (SAL) increased the intracellular uptake of propidium iodide (PI) and sunitinib (SU). Herein, we investigated whether SAL pretreatment affects the intracellular uptake and cytotoxic effects of molecular-targeted drugs in RCC cells. We analyzed Gb3 expression in TOS1, TOS3, TOS3LN, and ACHN human RCC cells. Surface Gb3 expression was higher in TOS1 and TOS3 cells than in TOS3LN and ACHN cells. In the PI uptake assay, 41.5% of TOS1 cells and 21.1% of TOS3 cells treated with SAL were positive for PI. TOS1 cell viability decreased to 70% after treatment with 25 µM SU alone and to 48% after pretreatment with SAL (50 µg/mL). Time-series measurements of the intracellular fluorescence of SU revealed significantly enhanced SU uptake in SAL-treated TOS1 cells compared to control cells. SAL treatment did not increase PI uptake in normal renal cells. Our findings suggest that adequate cytotoxic activity may be achieved even when SU is administered at a sufficiently low dose not to cause side effects in combination with SAL.